CDNA CareDx, Inc. gains 33% May 14, 2018

CareDx, Inc., a molecular diagnostics company, focuses on the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients in the United States and internationally. The company's commercialized testing solution includes the AlloMap heart transplant molecular test (AlloMap), a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function who have a low probability of moderate/severe acute cellular rejection. It is also developing AlloSure, a next-generation sequencing-based test to detect donor-derived cell-free DNA after transplantation. The company markets its AlloMap solution to healthcare providers through its direct sales force that targets transplant centers and their physicians, coordinators, and nurse practitioners. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in Brisbane, California.http://www.priceseries.com/trade/CDNA-CareDx-Inc-stock-gains-33-percent-a-Trade-Record-by-priceSeries-2018040320180514.html